Phase Forward Revenues Up 23%

Wednesday, October 29, 2008 09:22 AM

Waltham, Mass.-based eClinical technology company Phase Forward reported a 23% jump in third quarter revenues to $43 million from $34.9 million in the third quarter of 2007.

Non-GAAP net income for the period slid to $5.4 million compared with $6.9 million in the third quarter of 2007. The decline was due primarily to an increase in the company’s tax rate from 10.3% in the third quarter of 2007 to 36.2%, according to Phase Forward president and CEO Bob Weiler.

Weiler mentioned a number of Q3 highlights for the company, including a multi-year extension agreement with Eli Lilly and the recent acquisition of Clarix, a privately held provider of Web-integrated interactive response technology (IRT) based in Radnor, Pa.

“We continue to be optimistic about Phase Forward’s long-term opportunity, particularly considering the fact that we have recently expanded our market opportunity and value proposition with the acquisition of Clarix and its next generation interactive response technologies,” Weiler said in a company release. “The company’s broad range of offerings combined with our strong, debt-free balance sheet makes Phase Forward a financially secure business partner.”

Phase Forward's shares closed down 1.8% at $13.08 on Tuesday.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs